The global neovascular age-related macular degeneration treatment market is expected to garner a market value of USD 3 billion in 2023 and is expected to accumulate a market value of USD 4.89 billion by registering a CAGR of 5% in the forecast period 2023 to 2033.
The market for neovascular age-related macular degeneration treatment registered a CAGR of 3.5% in the historical period 2018 to 2022.
The Neovascular Age-related Macular Degeneration Treatment market is a segment of the healthcare industry that deals with the effective management of the condition. The market is expected to grow significantly in the coming years due to the increasing prevalence of the condition worldwide. Neovascular age-related macular degeneration is a serious eye condition that affects older adults and can lead to vision loss. The treatment of nAMD typically involves medications that are injected into the eye to stop the growth of abnormal blood vessels in the retina. These medications are known as anti-VEGF drugs.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 3 billion |
| Anticipated Forecast Value (2033) | USD 4.89 billion |
| Projected Growth Rate (2023 to 2033) | 5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider, Future Market Insights- the market for Neovascular Age-related Macular Degeneration Treatment reflected a value of 3.5% during the historical period, 2018 to 2022.
The neovascular age-related macular degeneration treatment market has been growing rapidly in recent years due to the increasing prevalence of nAMD and the availability of effective drugs for its treatment. The market is expected to continue growing in the coming years as the aging population continues to grow.
The key players in the neovascular age-related macular degeneration treatment market include pharmaceutical companies such as Roche, Novartis, Regeneron, and Bayer. These companies are investing heavily in research and development to bring new and improved drugs to market for the treatment of nAMD. In addition to anti-VEGF drugs, other treatments for nAMD are also being developed, including gene therapy and sustained-release drug delivery systems. These new treatments have the potential to improve patient outcomes and reduce the need for frequent injections.
Moreover, strategic collaborations, mergers and acquisitions, and product innovations are expected to further drive the growth of the Neovascular Age-related Macular Degeneration Treatment market. Key players in the market are investing in R&D activities to develop new treatment options and improve the efficacy of existing ones.
The market offers growth opportunities for pharmaceutical companies, medical device manufacturers, and healthcare providers. Overall, the market for neovascular age-related macular degeneration treatment is expected to register a CAGR of 5% in the forecast period 2023 to 2033.
Growing Awareness along with increasing prevalence of Focal Segmental Glomerulosclerosis (FSGS) to drive growth
The neovascular age-related macular degeneration (nAMD) treatment market has been experiencing significant growth in recent years and is expected to continue growing in the coming years. Several factors are driving this growth, including:
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
The cost of nAMD treatment with anti-VEGF drugs can be very high, and this can limit patient access to these treatments. Some patients may not be able to afford the cost of treatment, while others may face limitations in their insurance coverage.
Moreover, Anti-VEGF drugs are typically administered through injections directly into the eye, which can be uncomfortable and inconvenient for patients. Additionally, these injections need to be given on a regular basis, which can be challenging for patients who have difficulty traveling to clinics or for those who may be homebound.
Increasing awareness and diagnosis of the condition Shaping Landscape in South & East Asia
The neovascular age-related macular degeneration (nAMD) treatment market is turning out to be promising in the South & East Asia region. The prevalence of nAMD is increasing in the region due to aging populations, changing lifestyles, and increasing prevalence of diabetes.
Several pharmaceutical companies have been focusing on expanding their market presence in the region by investing in research and development, strategic partnerships, and collaborations. For example, Novartis and Roche have been leading players in the nAMD treatment market in the region, and have been expanding their product portfolios and conducting clinical trials for new treatments.
In addition, the availability of biosimilars of anti-VEGF drugs has increased in the region, which has made treatment more affordable for patients. The use of biosimilars has also increased competition in the market, leading to more affordable treatment options. However, challenges remain in the region, including limited access to specialized ophthalmologists, inadequate healthcare infrastructure in some areas, and low awareness of nAMD and its treatment options among patients and healthcare providers.
Overall, the nAMD treatment market in South & East Asia is expected to continue growing in the coming years, driven by factors such as increasing patient awareness, expanding healthcare infrastructure, and the introduction of new treatments.
Increasing Focus on technological advancements driving demand for Neovascular Age-related Macular Degeneration Treatment in North America
The aging population in North America is contributing to the increasing prevalence of nAMD. According to the American Academy of Ophthalmology, more than 10 million Americans are affected by AMD, with nAMD accounting for a significant portion of these cases.
North America is at the forefront of research and development of new nAMD treatments, and the availability of advanced treatment options such as anti-VEGF drugs has contributed to the growth of the market. Additionally, the introduction of gene therapy and sustained-release drug delivery systems has further expanded treatment options.
The strong healthcare infrastructure in North America has contributed to the growth of the nAMD treatment market, with access to specialized ophthalmologists, well-equipped healthcare facilities, and advanced diagnostic and treatment technologies. The increasing awareness of nAMD and its treatment options among patients and healthcare providers has contributed to the growth of the market. Patients are now seeking earlier diagnosis and treatment, which has increased the demand for effective nAMD treatments.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Wet AMD segment to hold a significant share and push market growth
Wet AMD is likely to account for a significant share in the Neovascular Age-related Macular Degeneration Treatment market is Wet AMD. Wet AMD is a more severe form of the disease and can progress rapidly, causing severe vision loss or blindness if left untreated.
This has led to a higher demand for treatments that can effectively manage the condition, such as anti-vascular endothelial growth factor (anti-VEGF) drugs. These drugs are used to block the growth of abnormal blood vessels and reduce fluid leakage in the retina, slowing down the progression of the disease and improving vision.
Late-stage AMD segment to hold a significant share and push market growth
Among the different stages of AMD, the Late-stage AMD segment is likely to account for a significant share in the neovascular age-related macular degeneration treatment market.
Late-stage AMD includes both wet AMD and geographic atrophy, which are advanced forms of the disease that can cause severe vision loss or blindness if left untreated. As a result, there is a higher demand for effective treatments for late-stage AMD, such as anti-vascular endothelial growth factor (anti-VEGF) drugs, which can help slow down the progression of the disease and improve vision.
Key players in the market include companies such as Competition Deep Dive, Competition Deep Dive, Bausch & Lomb Incorporate, Novartis AG, Pfizer Inc., ALLERGAN, Acucela Inc., Santen Pharmaceuticals Co., Ophthotech Corporation, Alimera Sciences Inc.
GlaxoSmithKline PLC, Regeneron Pharmaceutical Inc., Bayer AG, Rxi Pharmaceuticals Inc. along with healthcare providers and technology companies among other global players.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 3 billion |
| Market Value in 2033 | USD 4.89 billion |
| Growth Rate | CAGR of 5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
Disease Type, Drug Type, Age group, Gender, Stage of Disease, Distribution Channel, Region |
| Regions Covered |
North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled |
United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | F. Hoffmann- La Roche AG; Bausch + Lomb; Novartis AG; Pfizer Inc.; Allergan Plc.; Acucela Inc.; Santen Pharmaceuticals Co.; Ophthotech Corporation; Alimera Sciences Inc.; GSK plc.; Regeneron Pharmaceuticals Inc.; Bayer AG; RXi Pharmaceuticals Inc. |
| Customization | Available Upon Request |
The neovascular age-related macular degeneration treatment market size reaches USD 3 billion in 2023.
The market is set to surge at a 5% CAGR, reaching a valuation of USD 4.89 billion by 2033.
The market witnessed a 3.5% CAGR between 2018 and 2022.
The United States exhibits promising potential for neovascular age-related macular degeneration treatment due to its advanced healthcare infrastructure.
The Wet AMD segment demonstrates significant expansion in the neovascular age-related macular degeneration treatment market.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 5.1. Ranibizumab 5.2. Aflibercept 5.3. Bevacizumab 5.4. Brolucizumab 5.5. Faricimab 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type 6.1. Dry AMD 6.2. Wet AMD 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Age Group 7.1. Less Than 60 7.2. Between 60 to 80 7.3. More Than 80 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Gender 8.1. Male 8.2. Female 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Stage of Disease 9.1. Early-stage AMD 9.2. Intermediate AMD 9.3. Late-stage AMD 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 10.1. Hospital Pharmacy 10.2. Specialty Pharmacy 10.3. Online Pharmacy 11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 11.1. North America 11.2. Latin America 11.3. Europe 11.4. South Asia 11.5. East Asia 11.6. Oceania 11.7. MEA 12. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 18. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 19. Key Countries Market Analysis 20. Market Structure Analysis 21. Competition Analysis 21.1. F.Hoffmann-La Roche AG 21.2. Bausch + Lomb 21.3. Novartis AG 21.4. Pfizer Inc. 21.5. Allergan Plc. 21.6. Acucela Inc. 21.7. Santen Pharmaceuticals Co. 21.8. Ophthotech Corporation 21.9. Alimera Sciences Inc. 21.10. GSK plc. 21.11. Regeneron Pharmaceuticals Inc. 21.12. Bayer AG 21.13. RXi Pharmaceuticals Inc. 22. Assumptions & Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Neovascular Age-related Macular Degeneration Treatment Market
